Chemotherapy
Safety of secondary CRS/HIPEC in peritoneal surface malignancies: Insights from a national cohort study
European Journal of Surgical Oncology 2026 January 17 [Link] Lukas Pollmann, Jürgen Zieren, Nicola S Pollmann, Urs Giger-Pabst, Pompiliu Piso, Michael Ströhlein, Nicola Cerasani, Fabian Kockelmann, Maximilian Schmeding Abstract Background: For carefully selected patients with peritoneal surface malignancies (PSMs), secondary cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can provide similar oncological results as…
Read MoreCancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma
Cancer Science 2026 January 20 [Link] Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka Abstract Pleural mesothelioma (PM) is a malignancy with a poor prognosis owing to its resistance to…
Read MoreRisk Factors of Hematological Toxicity of Mesothelioma Treatment-A Territory-Wide Retrospective Study
Thoracic Cancer 2026 January [Link] Wang Chun Kwok, Desmond Yat Hin Yap, Isaac Sze Him Leung, James Chung Man Ho Abstract Background: While chemotherapy remains the treatment of choice for mesothelioma, it carries significant toxicities, especially hematological toxicity. Methods: We conducted this territory-wide retrospective study in Hong Kong to investigate the prevalence and risk factors…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreCytoreductive surgery and HIPEC for multicystic peritoneal mesothelioma: therapeutic approach in a rare benign neoplasm
Journal of Surgical Case Reports 2026 January 8 [Link] Goran Aleksandrić, Nemanja Trifunović, Jovana Trifunović, Sara Filipović, Nebojša Mitrović Abstract Multicystic peritoneal mesothelioma (MCPM) is an uncommon tumor of mesothelial origin, characterized by multiple interconnected cystic spaces and uncertain biological behavior. Although traditionally considered benign, its tendency to recur and occasionally spread within the peritoneal…
Read MoreReal-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang Abstract Background: Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However,…
Read MoreReal-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang Abstract Background: Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However,…
Read MoreEpithelioid Mesothelioma Cells Exhibit Increased Ferroptosis Sensitivity Compared to Non-Epithelioid Mesothelioma Cells
Cancers 2025 December 13 [Link] Tatsuhiro Sato, Ikue Hasegawa, Haruna Ikeda, Taichi Ohshiro, Lisa Kondo-Ida, Satomi Mukai, Satoshi Ohte, Tohru Maeda, Yoshitaka Sekido Abstract Background/Objectives: Mesothelioma is a highly aggressive tumor with a poor prognosis that typically develops after a long latency period following asbestos exposure. Although immunotherapy combined with chemotherapy is increasingly used, the…
Read MoreCurcumin impacts on cisplatin sensitivity determining apoptotic boost in mesothelioma
Biomedicine & Pharmacotherapy 2025 December [Link] Miriam Piccioni, Emilia Caputo, Rossana Cuciniello, Francesco Di Meo, Anna Valentino, Gianluigi Petillo, Elena Rinaldi, Orsolina Petillo, Alfonso Baldi, Stefania Filosa, Paolo Bergamo, Stefania Crispi Abstract Cancer is one of the main diseases causing one-third of the worldwide death every year. The recent progresses achieved in chemotherapy have increased…
Read More
Skip to content